Urokinase

Pharmacokinetics

 

It directly
converts plasminogen to active plasma.

TOP

   

Indication
& Dosage

 

PULMONARY
EMBOLISM (PE), DEEP VEIN THROMBOSIS (DVT):

Initially 4400 IU/kg over 10
min followed by 4400 IU/kg/hr. Alternatively in PE, 15000 IU/kg may be
given as bolus injection into pulmonary artery repeated every 24 hrs for
3 doses.

Intra coronary ACUTE MI : 6000 IU/min for up to
2 hrs should be preceded
by IV heparin or IV doses of UK at 2-3 mio units over 45 to 90 min.




Catheter


PERIPHERAL VASCULAR OCCLUSION: 4000 UNITS/MIN via a catheter into the
clot as a solution containing 2500 unit/ml. Catheter is advanced into
the occlusion every 2 hrs until free flow is resumed.

CLEARANCE OF OCCLUDED CATHETERS AND SHUNTS: Up to 25000 units in 2-3 ml
of 0.9% Nacl instilled and clamped off for 2-4 hrs

TOP

   

Action

 



A thrombolytic agent obtained from human kidney cells by tissue culture.
Urokinase directly convert plasminogen into plasmin which then degrades
fibrin clots as well as fibrinogen and other plasma proteins.

TOP

   

Interactions

 

Aspirin, Cefamandole, Divalproex,
Enoxaparin, Heparin, Indomethacin, anti-inflammatory drugs or analgesics
(except narcotics), Phenylbutazone, Plicamycin, Sulfinpyrazone,
Ticlopidine or Valproic acid: when used together with Urokinase
increases the chances of bleeding .

TOP



   

Adverse
Effect & Precaution



Drug fever, haemorrhage

  

Allergies:
Allergic reaction to Urokinase may occur. Pregnancy :There is a slight
chance that use of a thrombolytic agent during the first five months of
pregnancy may cause a miscarriage. Older adults: The need for treatment
with a thrombolytic agent may be increased in elderly patients with
blood clots, however, the chance of bleeding may also be increased.

Pregnancy: Safety not established.

Breast Feeding: Safety not establishe.

Man: Use with caution.

TOP

    

Brand
available in market